*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# 瑋俊生物科技有限公司

# Wai Chun Bio-Technology Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 660)**

## DELAY IN DESPATCH OF CIRCULAR

References are made to the announcements of Wai Chun Bio-Technology Limited (the "**Company**") dated 14 April 2025, 14 May 2025, 10 June 2025, 25 June 2025 and 15 July 2025, in relation to, among other things, the connected transaction for proposed issue of New Convertible Bonds under specific mandate and the delay in dispatch of circular (the "**Announcements**"). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcements, a circular (the "**Circular**") containing, among other things, (i) further information of the Subscription and the transactions contemplated thereunder (including the grant of the New Convertible Bonds Specific Mandate); (ii) the recommendation of the Independent Board Committee to the Independent Shareholders in relation to the Subscription; (iii) the letter of advice from the Independent Financial Adviser; (iv) details of the New Convertible Bonds; and (v) notice of the EGM, is expected to be despatched to the Shareholders on or before Thursday, 31 July 2025.

As additional time is required to finalise certain information in the Circular, the Circular is expected to be despatched to the Shareholders on or before Friday, 15 August 2025.

By Order of the Board
**Wai Chun Bio-Technology Limited**
**Lam Ka Chun**
*Chairman and Chief Executive Officer*

Hong Kong, 31 July 2025

*As at the date of this announcement, the Board consists of one executive director, namely Mr. Lam Ka Chun and three independent non-executive Directors, namely Mr. Wang Ziniu, Ms. Xu Huiling and Mr. Wong Po Keung.*